FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024685636> ?p ?o ?g. }

• W2024685636 endingPage "2186" @default.
• W2024685636 startingPage "2176" @default.
• W2024685636 abstract "Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy.BackgroundRenal relapse in lupus nephritis has been shown to have ominous prognostic significance with the majority of patients progressing to doubling of serum creatinine (CRX2). However, not all patients do so. This report explores the roles of response of inflammation to therapy and of glomerular scarring and interstitial fibrosis and their potential reversal to outcome of renal relapse.MethodsRenal biopsies from 71 patients with lupus nephritis with an initial biopsy (Bx1) and systematic control biopsy (Bx2) after six months of therapy, as well as subsequent biopsies for clinical indications, were studied. The relationships of morphologic factors to renal relapse and its outcome as well as to CRX2 and end-stage renal disease (ESRD) were analyzed. Cox proportional hazards modeling was used to assess association of morphologic variables with outcomes.ResultsRenal interstitial fibrosis and glomerular segmental scarring were partially reversible in 17 and 11 patients, respectively. This decline was associated with an excellent prognosis, with only one patient in each group (5.9% and 9.1% respectively) progressing to CRX2. All 18 patients who progressed to CRX2 either failed to respond to therapy (7 patients) as defined by normalization of serum creatinine (SCr) and reduction of proteinuria to ≤1 g/day, or relapsed after initial response (11 patients), as defined by recent rise of SCr>50% and/or proteinuria>3.5 g/day. However, relapse also occurred in 11 of 47 other patients without progression to CRX2. These patients showed a greater initial response of inflammation and deposits to therapy and fibrous lesions partially reversed in the period prior to relapse, so that active lesions were superimposed on a lower level of chronic lesions. By contrast, chronic lesions mounted steadily in those who progressed to CRX2. Cox proportional hazards modeling indicated a strong association of inflammatory variables with renal relapse, CRX2 and ESRD. However, the extent of immunoglobulin deposits was not significantly associated with any outcome. Finally, we found that failure of disease to remit also is associated with a high rate of CRX2 (64.8% vs. 13.0%, P = 0.00034).ConclusionsInterstitial fibrosis and glomerular scarring in systemic lupus erythematosus are partially reversible, and this reversal is attended by an excellent outcome. The outcome of renal relapse is determined by the initial response of inflammatory and chronicity elements to therapy, those with prior partial reversal of interstitial and glomerular scarring having a good outcome, and those in whom fibrotic lesions have continued to increase and have a poor outcome. Inflammatory variables appear to be more important in determining outcome than immunoglobulin deposits. Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy. Renal relapse in lupus nephritis has been shown to have ominous prognostic significance with the majority of patients progressing to doubling of serum creatinine (CRX2). However, not all patients do so. This report explores the roles of response of inflammation to therapy and of glomerular scarring and interstitial fibrosis and their potential reversal to outcome of renal relapse. Renal biopsies from 71 patients with lupus nephritis with an initial biopsy (Bx1) and systematic control biopsy (Bx2) after six months of therapy, as well as subsequent biopsies for clinical indications, were studied. The relationships of morphologic factors to renal relapse and its outcome as well as to CRX2 and end-stage renal disease (ESRD) were analyzed. Cox proportional hazards modeling was used to assess association of morphologic variables with outcomes. Renal interstitial fibrosis and glomerular segmental scarring were partially reversible in 17 and 11 patients, respectively. This decline was associated with an excellent prognosis, with only one patient in each group (5.9% and 9.1% respectively) progressing to CRX2. All 18 patients who progressed to CRX2 either failed to respond to therapy (7 patients) as defined by normalization of serum creatinine (SCr) and reduction of proteinuria to ≤1 g/day, or relapsed after initial response (11 patients), as defined by recent rise of SCr>50% and/or proteinuria>3.5 g/day. However, relapse also occurred in 11 of 47 other patients without progression to CRX2. These patients showed a greater initial response of inflammation and deposits to therapy and fibrous lesions partially reversed in the period prior to relapse, so that active lesions were superimposed on a lower level of chronic lesions. By contrast, chronic lesions mounted steadily in those who progressed to CRX2. Cox proportional hazards modeling indicated a strong association of inflammatory variables with renal relapse, CRX2 and ESRD. However, the extent of immunoglobulin deposits was not significantly associated with any outcome. Finally, we found that failure of disease to remit also is associated with a high rate of CRX2 (64.8% vs. 13.0%, P = 0.00034). Interstitial fibrosis and glomerular scarring in systemic lupus erythematosus are partially reversible, and this reversal is attended by an excellent outcome. The outcome of renal relapse is determined by the initial response of inflammatory and chronicity elements to therapy, those with prior partial reversal of interstitial and glomerular scarring having a good outcome, and those in whom fibrotic lesions have continued to increase and have a poor outcome. Inflammatory variables appear to be more important in determining outcome than immunoglobulin deposits." @default.
• W2024685636 created "2016-06-24" @default.
• W2024685636 creator A5005741040 @default.
• W2024685636 creator A5025017467 @default.
• W2024685636 creator A5027091386 @default.
• W2024685636 creator A5038248105 @default.
• W2024685636 creator A5044141185 @default.
• W2024685636 creator A5059751677 @default.
• W2024685636 creator A5074221866 @default.
• W2024685636 creator A5089507696 @default.
• W2024685636 date "2002-06-01" @default.
• W2024685636 modified "2023-09-25" @default.
• W2024685636 title "Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy" @default.
• W2024685636 cites W1491038651 @default.
• W2024685636 cites W1608810958 @default.
• W2024685636 cites W1622673329 @default.
• W2024685636 cites W1971346247 @default.
• W2024685636 cites W1975305530 @default.
• W2024685636 cites W1995752760 @default.
• W2024685636 cites W1997166449 @default.
• W2024685636 cites W2002602200 @default.
• W2024685636 cites W2003820403 @default.
• W2024685636 cites W2009355282 @default.
• W2024685636 cites W2015609157 @default.
• W2024685636 cites W2018384883 @default.
• W2024685636 cites W2022472705 @default.
• W2024685636 cites W2023919440 @default.
• W2024685636 cites W2026819380 @default.
• W2024685636 cites W2028911415 @default.
• W2024685636 cites W2064999867 @default.
• W2024685636 cites W2066909420 @default.
• W2024685636 cites W2071299644 @default.
• W2024685636 cites W2072719607 @default.
• W2024685636 cites W2085406842 @default.
• W2024685636 cites W2089137362 @default.
• W2024685636 cites W2092159811 @default.
• W2024685636 cites W2096819251 @default.
• W2024685636 cites W2101907901 @default.
• W2024685636 cites W2104492395 @default.
• W2024685636 cites W2123559949 @default.
• W2024685636 cites W2124360695 @default.
• W2024685636 cites W2153820664 @default.
• W2024685636 cites W2286727159 @default.
• W2024685636 doi "https://doi.org/10.1046/j.1523-1755.2002.00357.x" @default.
• W2024685636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12028458" @default.
• W2024685636 hasPublicationYear "2002" @default.
• W2024685636 type Work @default.
• W2024685636 sameAs 2024685636 @default.
• W2024685636 citedByCount "68" @default.
• W2024685636 countsByYear W20246856362012 @default.
• W2024685636 countsByYear W20246856362013 @default.
• W2024685636 countsByYear W20246856362014 @default.
• W2024685636 countsByYear W20246856362015 @default.
• W2024685636 countsByYear W20246856362016 @default.
• W2024685636 countsByYear W20246856362017 @default.
• W2024685636 countsByYear W20246856362018 @default.
• W2024685636 countsByYear W20246856362019 @default.
• W2024685636 countsByYear W20246856362020 @default.
• W2024685636 countsByYear W20246856362021 @default.
• W2024685636 countsByYear W20246856362022 @default.
• W2024685636 crossrefType "journal-article" @default.
• W2024685636 hasAuthorship W2024685636A5005741040 @default.
• W2024685636 hasAuthorship W2024685636A5025017467 @default.
• W2024685636 hasAuthorship W2024685636A5027091386 @default.
• W2024685636 hasAuthorship W2024685636A5038248105 @default.
• W2024685636 hasAuthorship W2024685636A5044141185 @default.
• W2024685636 hasAuthorship W2024685636A5059751677 @default.
• W2024685636 hasAuthorship W2024685636A5074221866 @default.
• W2024685636 hasAuthorship W2024685636A5089507696 @default.
• W2024685636 hasBestOaLocation W20246856361 @default.
• W2024685636 hasConcept C126322002 @default.
• W2024685636 hasConcept C159641895 @default.
• W2024685636 hasConcept C2775934546 @default.
• W2024685636 hasConcept C2776914184 @default.
• W2024685636 hasConcept C2777058396 @default.
• W2024685636 hasConcept C2779134260 @default.
• W2024685636 hasConcept C2779561371 @default.
• W2024685636 hasConcept C2779912601 @default.
• W2024685636 hasConcept C2780091579 @default.
• W2024685636 hasConcept C2780306776 @default.
• W2024685636 hasConcept C2780559512 @default.
• W2024685636 hasConcept C2780888721 @default.
• W2024685636 hasConcept C2781087799 @default.
• W2024685636 hasConcept C71924100 @default.
• W2024685636 hasConcept C90924648 @default.
• W2024685636 hasConceptScore W2024685636C126322002 @default.
• W2024685636 hasConceptScore W2024685636C159641895 @default.
• W2024685636 hasConceptScore W2024685636C2775934546 @default.
• W2024685636 hasConceptScore W2024685636C2776914184 @default.
• W2024685636 hasConceptScore W2024685636C2777058396 @default.
• W2024685636 hasConceptScore W2024685636C2779134260 @default.
• W2024685636 hasConceptScore W2024685636C2779561371 @default.
• W2024685636 hasConceptScore W2024685636C2779912601 @default.
• W2024685636 hasConceptScore W2024685636C2780091579 @default.
• W2024685636 hasConceptScore W2024685636C2780306776 @default.
• W2024685636 hasConceptScore W2024685636C2780559512 @default.
• W2024685636 hasConceptScore W2024685636C2780888721 @default.
• W2024685636 hasConceptScore W2024685636C2781087799 @default.

• next